Navigation Links
Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Adrian Schwarzer, MD, Ph.D. to its Scientific Advisory Committee
Date:12/23/2013

MILLBROOK, N.Y., Dec. 23, 2013 /PRNewswire/ -- Dr. Schwarzer is affiliated with Hannover Medical School in Hannover, Germany at the Institute of Experimental Hematology and resident in the Department of Hematology, Oncology and Stem Cell Transplantation. Dr. Schwarzer has an MD in Immunology and Ph.D. in Molecular Medicine/Biochemistry. He is currently engaged in investigating the role of cap dependent translation in acute lymphoblastic leukemias with a special focus on T-ALL.

We at Egenix are delighted to have Dr. Schwarzer aboard and feel confident that he will make significant contributions to the advancement of science and medicine.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com

 


'/>"/>
SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. KaloBios Appoints Donald R. Joseph as Chief Legal Officer
2. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair
3. Imaging Contract-Research Pioneer, Donald P. Rosen, MD, Named CEO of ACR Image Metrix™
4. Gregory Frank Named President of Two Leading Immunology Biotech Companies; Pure Protein and Pure MHC
5. Cargill’s Dielectric Transformer Oil Made from Natural Esters Wins Presidential Green Chemistry Award
6. The Leukemia & Lymphoma Societys "A Tribute to Jackie" Photo Collection Part of Auction Commemorating the 50th Anniversary of President Kennedys Assassination
7. TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, Nominated by President Barack Obama as Surgeon General of the United States of America
8. ISPE Names Dr. Thomas Zimmer as Vice President of European Operations
9. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
10. Sigma-Aldrich Corporation Delcares Quarterly Dividend Of $0.215 Per Share And Announces Election Of New Vice President And Treasurer
11. Gentris Corporation Partners with BioFortis, Announces New Vice President of Information Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake ... and elastic characteristics when deformed, which is identical to how the human discs ... compressive forces and return to its natural state along a hysteresis curve, exactly ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... -- According to a report by Transparency Market Research ... to the presence of a large pool of participants; however, only ... and Sigma-Aldrich, compete with each other in this market. With Proliant ... 76% of this market in 2016.  ... As of now, a large number of vendors ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers ... from small lab samples to full-size tissues, bones, even whole organs to implant ... system that delivers blood deep into the developing tissue. , Current bioengineering ...
Breaking Biology Technology:
(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
(Date:3/7/2017)... SALT LAKE CITY , March 7, 2017 /PRNewswire/ ... solutions that help top global companies identify the best ... Leonard as Chief Sales Officer (CSO) and ... and Kucer,s appointments round out a seasoned executive team poised ... year and beyond, building on a year of record ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
Breaking Biology News(10 mins):